30.67 USD
▼-1.07-3.37%
盘后 31.50 +2.71%
2026-11-19
市值
$542.49M
市盈率
—
EPS
-35.87
股息率
—
52 周区间
12.79 – 37.83
成交量
91.68K
Beta
0.56
目标价
63.50
52W 低 12.7952W 高 37.83
价格走势
公司简介
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular ag...